Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Myriad Genetics Inc (MYGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,199,065
  • Shares Outstanding, K 68,090
  • Annual Sales, $ 753,800 K
  • Annual Income, $ 125,300 K
  • 36-Month Beta 0.37
  • Price/Sales 1.60
  • Price/Cash Flow 8.55
  • Price/Book 1.66

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.50 +2.80%
on 04/20/17
19.66 -8.49%
on 03/27/17
-1.39 (-7.17%)
since 03/24/17
3-Month
15.15 +18.75%
on 02/07/17
19.90 -9.60%
on 03/14/17
+1.98 (+12.37%)
since 01/24/17
52-Week
15.15 +18.75%
on 02/07/17
37.83 -52.45%
on 04/28/16
-19.45 (-51.95%)
since 04/22/16

Most Recent Stories

More News
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?

Myriad Genetics, Inc. (MYGN) is scheduled to report third-quarter fiscal 2017 results on May 2, after the closing bell.

SYRS : 15.16 (+1.74%)
GALT : 3.12 (+0.97%)
MYGN : 17.91 (+1.70%)
HRC : 71.97 (+1.17%)
Myriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017

Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 2, 2017....

MYGN : 17.91 (+1.70%)
Look for Shares of Myriad Genetics to Potentially Rebound after Yesterday's 1.27% Sell Off

Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $17.76 to a high of $18.11. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $18.00...

MYGN : 17.91 (+1.70%)
Myriad Genetics Down 48.2% Since SmarTrend Downtrend Call (MYGN)

SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 12 months, Myriad Genetics has returned 48.21% as of today's recent price of $17.97.

MYGN : 17.91 (+1.70%)
Myriad Genetics Reaches Analyst Target Price

In recent trading, shares of Myriad Genetics, Inc. have crossed above the average analyst 12-month target price of $18.10, changing hands for $18.15/share.

MYGN : 17.91 (+1.70%)
Watch for Myriad Genetics to Potentially Rebound After Falling 1.62% Yesterday

Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $18.16 to a high of $18.60. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $18.45...

MYGN : 17.91 (+1.70%)
Myriad Genetics Set to Possibly Rebound After Yesterday's Selloff of 1.62%

Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $18.16 to a high of $18.60. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $18.45...

MYGN : 17.91 (+1.70%)
Myriad Genetics Has Returned 47.5% Since SmarTrend Recommendation (MYGN)

SmarTrend identified a Downtrend for Myriad Genetics (NASDAQ:MYGN) on May 4th, 2016 at $34.70. In approximately 11 months, Myriad Genetics has returned 47.52% as of today's recent price of $18.21.

MYGN : 17.91 (+1.70%)
Myriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene's Novel PARP Inhibitor, BGB-290

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has entered into a companion diagnostic development collaboration with BeiGene,...

MYGN : 17.91 (+1.70%)
Pivotal Study Results for Myriad's myPath(R) Melanoma Test Highlighted In Two Additional Scientific Publications

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has published the third clinical validation study and second clinical utility study...

MYGN : 17.91 (+1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease....

See More

Support & Resistance

2nd Resistance Point 17.96
1st Resistance Point 17.78
Last Price 17.91
1st Support Level 17.49
2nd Support Level 17.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.